Beijing Institute of Technology (BIT) has described erythromycin derivatives reported to be useful for the treatment of bacterial infections.

Mitsubishi Tanabe Pharma Corp. has identified serine/threonine-protein salt-inducible kinases (SIK) inhibitors reported to be useful for the treatment of psoriatic arthritis, lupus nephritis, osteoarthritis, pancreatitis, rheumatoid arthritis, Sjögren’s syndrome, systemic lupus erythematosus and ulcerative colitis, among others.

Sudo Biosciences Ltd. has synthesized non-receptor tyrosine-protein kinase TYK2 (JH2 domain) inhibitors reported to be useful for the treatment of rheumatoid arthritis, multiple sclerosis, lupus and more.

Beth Israel Deaconess Medical Center Inc. has disclosed dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitors reported to be useful for the treatment of cancer, autoimmune disease and more.

Alexander Shulgin Research Institute has described phenylalkylamine compounds reported to be useful for the treatment of pain, inflammation, neurodegeneration, stroke, ischemia-reperfusion injury and psychiatric disorders.

University of Washington has divulged compounds acting as methionyl-tRNA synthetase (bacterial) inhibitors reported to be useful for the treatment of bacterial and protozoal infections.

Beijing Double-Crane Runchuang Technology Co. Ltd. has identified fascin (FSCN1) inhibitors reported to be useful for the treatment of cancer.

Odyssey Therapeutics Inc. has synthesized CDK2/cyclin E1 inhibitors reported to be useful for the treatment of cancer.

Researchers at Chengdu Brilliant Pharmaceutical Co. Ltd. and Scinnohub Pharmaceutical Co. Ltd. have disclosed 15-hydroxyprostaglandin dehydrogenase inhibitors reported to be useful for the treatment of diabetes, osteoporosis and more.

Genescience Pharmaceuticals Co. Ltd. has identified fibroblast growth factor receptor 2 (FGFR2) and/or FGFR3 inhibitors reported to be useful for the treatment of cancer, osteochondrodysplasia and achondroplasia.